Lupin receives US FDA approval for raltegravir tablets USP, 600 mg: Our Bureau, Mumbai Thursday, May 8, 2025, 17:25 Hrs [IST] Global pharma major Lupin Limited (Lupin) announced t ...

Research and Development (R&D) Expenses: R&D expenses decreased to $5.8 million for the three months ended March 31, 2025, ...

Qure advances its Huntington’s program toward accelerated approval as PTC Therapeutics reports strong Phase 2 results. Learn ...

In a precedential decision issued May 6, 2025, the Federal Circuit reversed in part and vacated in part a Delaware district ...

The FDA has communicated to Stealth BioTherapeutics that it would not meet elamipretide’s PDUFA target date for the treatment of Barth syndrome.

Intellia will present additional data from the ongoing Phase 1/2 study in an oral presentation at the European Academy of ...

Operator: Good day and welcome to the CorMedix, Inc. First Quarter 2025 Financial Results Conference Call. All participants ...

An advocate for cancer patients has said that patients will "die waiting" for cancer treatments in Ireland after a study ...

State jobs are known for offering competitive benefits and enrollment in the nation’s largest public pension plan.

A common medication used to treat HIV and hepatitis B may offer unexpected protection against Alzheimer's disease.

Merck & Co.‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, ...

As part of the 10th Mediterranean Neuroscience Society Conference, we are excited to present this new collection of articles ...